Pharmafile Logo
Pharmafocus logo
Advanced Search

imbruvica

Showing 15 posts of 31 posts found.

abbvie_0

AbbVie’s Imbruvica secures fourth breakthrough therapy designation from US FDA

July 1, 2016
Medical Communications, Research and Development, Sales and Marketing AbbVie, US FDA, drug trial, imbruvica

US pharma firm AbbVie (NYSE: ABBV) said the US Food and Drug Administration has granted Imbruvica a fourth breakthrough therapy …

News
janssen_latest_logo_on_sign_closer

Janssen says Imbruvica shows improved PFS in blood cancer in long-term effectiveness study

June 14, 2016
Manufacturing and Production, Research and Development Janssen, blood cancer, drug trial, imbruvica

Janssen said late-stage studies to test long-term effectiveness for its Imbruvica (ibrutinib) in blood cancer showed improved progression free survival …

News
fda2outsideweb

FDA expands Imbruvica label with new survival data

May 11, 2016
Research and Development, Sales and Marketing AbbVie, FDA, Janssen, data, efficacy, expanded, imbruvica, label, late stage, phase III

The US Food and Drug Administration (FDA) has expanded the label of Imbruvica (ibrutinib) to include the data from recent …

News
abbvie_0

AbbVie’s Imbruvica gets US FDA okay as first-line treatment for CLL

March 7, 2016
Sales and Marketing AbbVie, Janssen, Janssen Biotech, US FDA, imbruvica

Drug maker AbbVie said the US Food and Drug Administration (FDA) has approved its Imbruvica (ibrutinib) as a first-line treatment …

News
janssen_latest_logo_on_sign

Janssen slams NICE decision on Imbruvica

March 2, 2016
Research and Development, Sales and Marketing CLL, Cancer, Cancer Drugs Fund, Janssen, Johnson & Johnson, NICE, imbruvica

Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that …

News
janssen_latest_logo_on_sign_closer

Strong cancer trial data for Janssen at ASH 2015

December 8, 2015
Research and Development Cancer, Janssen, darzalex, imbruvica, oncology

Janssen presented new cancer trial data at the 57th Annual American Society of Haematology (ASH) meeting Orlando, Florida – with …

News
Janssen image

European Imbruvica approval for Janssen

July 20, 2015
Medical Communications, Sales and Marketing B-cell lymphoma, EC, European Commission, Janssen, Waldenström’s Macroglobulinemia, imbruvica, rare cancer

Janssen has received final European sign-off for its oncology treatment Imbruvica (ibrutinib) as a treatment option for adult patients with …

News
J&J image

J&J strong pharma sales can’t offset Q1 losses

April 15, 2015
Sales and Marketing J&J, JJ, Q1, Waldenström's macroglobulinemia, Waldenström’s Macroglobulinemia, Zytiga, abiraterone acetate, financials, ibrutinib, imbruvica

Johnson & Johnson’s pharma division achieved worldwide sales of $7.7 billion in the first quarter of this year – but …

News
Amgen image

Amgen’s colorectal cancer drug EU approved

April 8, 2015
Sales and Marketing Amgen, Vectibix, ibrutinib, imbruvica, panitumumab, ristempa

The European Commission has shown Amgen’s cancer drug Vectibix the green light to treat patients in combination with chemotherapy for …

News
Abbbie image

AbbVie buys Pharmacyclics in $21 billion deal

March 5, 2015
Sales and Marketing AbbVie, Humira, Johnson and Johnson, Pharmacyclics, adalimumab, imbruvica

AbbVie has secured Californian biotech Pharmacyclics and beat Johnson & Johnson to gain control of blockbuster blood cancer therapy Imbruvica in …

News
J&J image

J&J leukaemia drug gets FDA go-ahead

January 30, 2015
Sales and Marketing FDA, J&J, JJ, Janssen, The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s macroglobulinemia (WM) – a rare indol, Waldenström’s Macroglobulinemia, ibrutinab, imbruvica, johnson

The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s …

News
Roche image

Roche and Pharmacyclics agree leukaemia pact

October 17, 2014
Research and Development, Sales and Marketing BMS, CLL, Cancer, Gazyva, Pharmacyclics, Roche, imbruvica, leukaemia

Pharmacyclics’s cancer drug Imbruvica will be tested in combination with Roche’s Gazyva in a new partnership announced by the firms. …

News
The study will be conducted by Janssen image

BMS, Pharmacyclics and Janssen collaborate on cancer

October 14, 2014
Research and Development, Sales and Marketing BMS, Janssen, Pharmacyclics, imbruvica, opdivo

Bristol-Myers Squibb, Pharmacyclics and Janssen are to collaborate on clinical trials combining BMS’s cancer drug Opdivo (nivolumab) with Janssen and …

News
EMA HQ

EMA approvals for rival blood cancer drugs

July 27, 2014
Research and Development, Sales and Marketing CLL, Gilead, Janssen, chronic lymphocytic leukaemia, imbruvica, zydelig

Gilead and Janssen are set to face off in Europe after the CHMP recommended both of their rival blood cancer …

News
Janssen image

FDA extends licence for Janssen’s Imbruvica

February 13, 2014
Sales and Marketing FDA, Janssen, durect, imbruvica, leukaemia

Janssen and partner Pharmacyclics have been given an extended FDA approval for their new blood cancer treatment Imbruvica. The US …

News
The Gateway to Local Adoption Series

Latest content

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026

Rare diseases – spinal muscular atrophy

January 30, 2026

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026